Bilobetin treatment ameliorates hyperlipidaemia, lipotoxicity and insulin resistance in rats by stimulating PPARα-mediated lipid catabolism.

Swertiamarin possesses anti-hyperglycemic, anti-hyperlipidemic, anti-diabetic activity and enhances β cell regeneration which causes reversal of diabetes. Swertiamarin also possesses significant wound healing, anti-inflammatory, antioxidant, hepatoprotective, peripheral and central antinociceptive properties. Swertiamarin inhibits the development of arthritis by modulating NF-κB/IκB and JAK2/STAT3 signaling, it acts as an anti-rheumatic agent.

Nelumol A, and nelumal A show a potency comparable to the endogenous ligand, they may as a valuable potential novel lead compound in the search for FXR agonists.